Biohaven's Verdiperstat Falls Flat in Multiple System Atrophy

Biohaven Pharma's latest update on its Phase III clinical trial to use verdiperstat as a potential treatment for multiple system atrophy (MSA) showed that it did not meet its expected outcomes.